The continent consumes a growing share of the world's pharmaceuticals and produces a small fraction of them. A convergence of policy, capital and painful memory is building a local industry at last.
The pandemic taught Africa a lesson it has not forgotten. When global supply chains strained, the continent found itself last in line for vaccines and essential medicines, dependent on imports for the overwhelming majority of what its 1.4 billion people consume. The experience converted pharmaceutical manufacturing from an industrial policy talking point into a matter of sovereignty, and the response now underway is one of the more consequential industrial stories of the decade.
The market logic stands on its own. African pharmaceutical demand is growing steadily, driven by population, urbanisation, expanding insurance schemes and a disease burden shifting toward chronic conditions that require sustained medication. Yet local production supplies only a modest share of that demand, concentrated in a handful of countries. The gap between what the continent swallows and what it makes is a market measured in tens of billions of dollars, currently served by freight from India, China and Europe.
Closing it is genuinely hard, which is why the gap persisted. Pharmaceutical manufacturing punishes subscale operations, and many past ventures failed by building plants sized for national markets that could not fill them. Quality certification to international standards is expensive and unforgiving, yet without it a manufacturer cannot sell to the donor funded programmes and cross border tenders that anchor volumes. Inputs remain a vulnerability, since active ingredients still come overwhelmingly from Asia, meaning local formulation reduces dependence without eliminating it. And skills are scarce, from qualified pharmacists to the validation engineers who keep a certified plant certified.
What has changed is that each constraint is being attacked simultaneously. The African medicines regulatory agency now taking shape promises harmonised approvals, converting fifty small markets into addressable regional ones. The continental trade framework gives locally made medicines tariff advantages and tender access. Development finance institutions have made pharma manufacturing a priority sector, funding plants and quality upgrades on terms commercial lenders would not. Global vaccine and pharmaceutical majors, pressed by governments and reading the politics correctly, are licensing technology and partnering on fill and finish facilities as a first rung on the manufacturing ladder. And a cohort of Indian, Gulf and African firms with deep generics experience is investing, bringing exactly the operating knowledge earlier ventures lacked.
The winning national formula is becoming visible. Countries that combine credible regulation, reliable power and industrial zones, pooled regional demand and procurement preferences for quality local production are pulling ahead as manufacturing bases. The winning company formula pairs realistic scope, often beginning with high volume essential generics and fill finish operations, with uncompromising quality investment and anchor offtake agreements secured before the plant is poured.
For investors, the sector offers something rare, a large structurally growing market with policy momentum at its back and defensible moats once quality certification is achieved. For health systems, local production promises shorter supply lines and eventually better prices, though only competition delivers the latter. And for the continent's industrial ambitions, medicines may prove the sector where the case for making rather than importing is easiest to sustain, because every stockout has a face. Dependence took fifty years to build. The next ten will determine how much of it gets unwound.
